| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Shock, Cardiogenic | 50 | 2024 | 734 | 10.250 |
Why?
|
| Myocardial Infarction | 229 | 2024 | 11891 | 9.900 |
Why?
|
| Acute Coronary Syndrome | 87 | 2023 | 2362 | 9.510 |
Why?
|
| Lactones | 23 | 2021 | 319 | 7.150 |
Why?
|
| Troponin I | 40 | 2023 | 634 | 6.460 |
Why?
|
| Coronary Care Units | 26 | 2024 | 235 | 5.800 |
Why?
|
| Troponin T | 30 | 2024 | 774 | 5.010 |
Why?
|
| Pyridines | 30 | 2021 | 2877 | 4.690 |
Why?
|
| Acetanilides | 21 | 2014 | 169 | 4.370 |
Why?
|
| Cardiology | 33 | 2024 | 1723 | 4.360 |
Why?
|
| Heart Failure | 105 | 2024 | 11835 | 4.350 |
Why?
|
| Natriuretic Peptide, Brain | 55 | 2024 | 1705 | 4.220 |
Why?
|
| Troponin | 28 | 2023 | 516 | 4.020 |
Why?
|
| Angina, Unstable | 43 | 2016 | 926 | 3.830 |
Why?
|
| Platelet Aggregation Inhibitors | 41 | 2024 | 3201 | 3.180 |
Why?
|
| Receptor, PAR-1 | 11 | 2019 | 114 | 2.880 |
Why?
|
| Piperazines | 24 | 2014 | 2520 | 2.770 |
Why?
|
| Thrombolytic Therapy | 59 | 2023 | 2108 | 2.630 |
Why?
|
| Registries | 41 | 2024 | 8449 | 2.390 |
Why?
|
| Secondary Prevention | 27 | 2021 | 1548 | 2.310 |
Why?
|
| Atherosclerosis | 21 | 2023 | 3524 | 2.290 |
Why?
|
| Hospital Mortality | 46 | 2024 | 5420 | 2.070 |
Why?
|
| Critical Care | 34 | 2024 | 2699 | 2.060 |
Why?
|
| Electrocardiography | 62 | 2022 | 6413 | 2.040 |
Why?
|
| Extracorporeal Membrane Oxygenation | 13 | 2024 | 1455 | 2.030 |
Why?
|
| Risk Assessment | 102 | 2024 | 24086 | 2.010 |
Why?
|
| Heart-Assist Devices | 15 | 2024 | 1290 | 2.010 |
Why?
|
| Peptide Fragments | 35 | 2024 | 5120 | 2.010 |
Why?
|
| Intensive Care Units | 27 | 2024 | 3737 | 1.970 |
Why?
|
| American Heart Association | 21 | 2024 | 1081 | 1.930 |
Why?
|
| Angioplasty, Balloon, Coronary | 25 | 2021 | 1880 | 1.910 |
Why?
|
| Growth Differentiation Factor 15 | 8 | 2024 | 192 | 1.870 |
Why?
|
| Coronary Disease | 41 | 2014 | 5993 | 1.840 |
Why?
|
| Myocardial Ischemia | 30 | 2024 | 2161 | 1.830 |
Why?
|
| Atrial Fibrillation | 15 | 2024 | 5201 | 1.820 |
Why?
|
| Stroke | 43 | 2024 | 9945 | 1.810 |
Why?
|
| Enalapril | 9 | 2024 | 313 | 1.800 |
Why?
|
| Tetrazoles | 13 | 2024 | 901 | 1.790 |
Why?
|
| Fibrinolytic Agents | 43 | 2020 | 2167 | 1.770 |
Why?
|
| Angiotensin Receptor Antagonists | 12 | 2024 | 1025 | 1.710 |
Why?
|
| Chest Pain | 12 | 2023 | 1106 | 1.680 |
Why?
|
| Double-Blind Method | 61 | 2024 | 12412 | 1.670 |
Why?
|
| Enoxaparin | 22 | 2010 | 397 | 1.650 |
Why?
|
| Humans | 556 | 2024 | 760261 | 1.620 |
Why?
|
| Embolism | 6 | 2023 | 408 | 1.580 |
Why?
|
| Muscle, Smooth, Vascular | 13 | 2021 | 1484 | 1.530 |
Why?
|
| Receptors, Thrombin | 5 | 2015 | 132 | 1.520 |
Why?
|
| Hemorrhage | 31 | 2024 | 3604 | 1.500 |
Why?
|
| Hemodynamics | 10 | 2024 | 4169 | 1.480 |
Why?
|
| Peripheral Arterial Disease | 10 | 2021 | 1305 | 1.460 |
Why?
|
| C-Reactive Protein | 42 | 2023 | 3822 | 1.450 |
Why?
|
| Cardiovascular Diseases | 51 | 2024 | 15740 | 1.440 |
Why?
|
| Cardiopulmonary Resuscitation | 3 | 2022 | 1004 | 1.420 |
Why?
|
| Angina Pectoris | 12 | 2018 | 969 | 1.420 |
Why?
|
| Enzyme Inhibitors | 16 | 2014 | 3726 | 1.410 |
Why?
|
| Pravastatin | 17 | 2016 | 393 | 1.400 |
Why?
|
| Biphenyl Compounds | 13 | 2024 | 988 | 1.390 |
Why?
|
| Aged | 231 | 2024 | 168995 | 1.380 |
Why?
|
| Heart Injuries | 3 | 2021 | 208 | 1.370 |
Why?
|
| Heptanoic Acids | 16 | 2012 | 347 | 1.370 |
Why?
|
| Prognosis | 92 | 2024 | 29636 | 1.340 |
Why?
|
| Middle Aged | 259 | 2024 | 220175 | 1.310 |
Why?
|
| Intra-Aortic Balloon Pumping | 7 | 2024 | 227 | 1.290 |
Why?
|
| Uracil | 4 | 2018 | 207 | 1.290 |
Why?
|
| Stroke Volume | 23 | 2024 | 5513 | 1.280 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2022 | 347 | 1.220 |
Why?
|
| Anticholesteremic Agents | 9 | 2022 | 988 | 1.210 |
Why?
|
| Male | 305 | 2024 | 359413 | 1.200 |
Why?
|
| Thrombosis | 11 | 2022 | 3052 | 1.200 |
Why?
|
| Treatment Outcome | 121 | 2024 | 64947 | 1.180 |
Why?
|
| Myocardial Reperfusion | 15 | 2014 | 347 | 1.170 |
Why?
|
| Female | 308 | 2024 | 391011 | 1.160 |
Why?
|
| Hospitalization | 41 | 2024 | 10761 | 1.130 |
Why?
|
| Shock | 3 | 2023 | 318 | 1.080 |
Why?
|
| Glycopeptides | 6 | 2016 | 220 | 1.050 |
Why?
|
| Acute Disease | 55 | 2024 | 7268 | 1.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 19 | 2024 | 12281 | 1.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 23 | 2023 | 3333 | 1.010 |
Why?
|
| Randomized Controlled Trials as Topic | 51 | 2024 | 10340 | 1.010 |
Why?
|
| Pyrroles | 16 | 2012 | 1137 | 1.000 |
Why?
|
| Coronary Artery Disease | 23 | 2023 | 6661 | 1.000 |
Why?
|
| Thiazoles | 4 | 2021 | 1509 | 1.000 |
Why?
|
| Consensus | 7 | 2024 | 3106 | 1.000 |
Why?
|
| Myocytes, Smooth Muscle | 5 | 2014 | 685 | 0.980 |
Why?
|
| Receptors, Notch | 9 | 2013 | 742 | 0.940 |
Why?
|
| Cardiovascular System | 3 | 2023 | 850 | 0.940 |
Why?
|
| Critical Illness | 10 | 2023 | 2709 | 0.930 |
Why?
|
| Risk Factors | 98 | 2024 | 74269 | 0.920 |
Why?
|
| Heparin | 21 | 2023 | 1655 | 0.920 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 18 | 2008 | 638 | 0.890 |
Why?
|
| Ventricular Dysfunction, Left | 8 | 2023 | 2129 | 0.880 |
Why?
|
| Peroxidase | 6 | 2016 | 604 | 0.880 |
Why?
|
| Calgranulin A | 3 | 2021 | 80 | 0.870 |
Why?
|
| Calgranulin B | 3 | 2021 | 86 | 0.870 |
Why?
|
| Patient Admission | 6 | 2020 | 1384 | 0.860 |
Why?
|
| Glucosides | 5 | 2024 | 536 | 0.830 |
Why?
|
| Coronary Circulation | 17 | 2019 | 1578 | 0.810 |
Why?
|
| Drug Combinations | 14 | 2024 | 2024 | 0.790 |
Why?
|
| Piperidines | 4 | 2018 | 1650 | 0.780 |
Why?
|
| Receptors, Cell Surface | 8 | 2013 | 2825 | 0.770 |
Why?
|
| Anticoagulants | 20 | 2024 | 4896 | 0.770 |
Why?
|
| Creatine Kinase, MB Form | 11 | 2014 | 211 | 0.770 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 13 | 2024 | 1521 | 0.750 |
Why?
|
| Galectin 3 | 3 | 2016 | 240 | 0.730 |
Why?
|
| Hedgehog Proteins | 5 | 2021 | 769 | 0.730 |
Why?
|
| Receptor, Notch1 | 6 | 2010 | 495 | 0.730 |
Why?
|
| Proteomics | 5 | 2024 | 3810 | 0.730 |
Why?
|
| Vascular Surgical Procedures | 4 | 2020 | 1469 | 0.720 |
Why?
|
| Myocardium | 11 | 2021 | 4688 | 0.720 |
Why?
|
| Heart Diseases | 8 | 2019 | 2809 | 0.720 |
Why?
|
| Predictive Value of Tests | 44 | 2021 | 15273 | 0.720 |
Why?
|
| Tyrosine | 8 | 2008 | 1440 | 0.710 |
Why?
|
| Death, Sudden, Cardiac | 10 | 2021 | 1572 | 0.710 |
Why?
|
| Recurrence | 34 | 2020 | 8487 | 0.700 |
Why?
|
| Myocarditis | 3 | 2024 | 766 | 0.700 |
Why?
|
| Blood Chemical Analysis | 2 | 2020 | 437 | 0.690 |
Why?
|
| Protein Precursors | 10 | 2016 | 1135 | 0.690 |
Why?
|
| CD40 Ligand | 6 | 2021 | 522 | 0.680 |
Why?
|
| Benzhydryl Compounds | 7 | 2024 | 942 | 0.680 |
Why?
|
| Cardiovascular Agents | 8 | 2021 | 864 | 0.680 |
Why?
|
| Thiophenes | 4 | 2014 | 587 | 0.680 |
Why?
|
| Time Factors | 48 | 2024 | 40133 | 0.670 |
Why?
|
| Coronary Artery Bypass | 12 | 2020 | 2273 | 0.650 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2021 | 688 | 0.650 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2024 | 1256 | 0.640 |
Why?
|
| Kaplan-Meier Estimate | 18 | 2019 | 6545 | 0.640 |
Why?
|
| Ischemia | 4 | 2021 | 1893 | 0.640 |
Why?
|
| Syndrome | 29 | 2020 | 3278 | 0.630 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 8 | 2019 | 152 | 0.630 |
Why?
|
| Troponin C | 2 | 2016 | 24 | 0.620 |
Why?
|
| Coronary Thrombosis | 6 | 2014 | 486 | 0.610 |
Why?
|
| Neprilysin | 5 | 2023 | 472 | 0.610 |
Why?
|
| Collagen Type I | 2 | 2019 | 615 | 0.600 |
Why?
|
| North America | 7 | 2024 | 1282 | 0.590 |
Why?
|
| Proportional Hazards Models | 25 | 2022 | 12532 | 0.590 |
Why?
|
| Triage | 8 | 2020 | 982 | 0.580 |
Why?
|
| Simvastatin | 5 | 2019 | 352 | 0.580 |
Why?
|
| Ticlopidine | 9 | 2014 | 895 | 0.580 |
Why?
|
| Atrial Natriuretic Factor | 10 | 2016 | 350 | 0.570 |
Why?
|
| Clinical Chemistry Tests | 2 | 2015 | 59 | 0.560 |
Why?
|
| Cyclopropanes | 2 | 2016 | 431 | 0.560 |
Why?
|
| Terminology as Topic | 6 | 2019 | 1534 | 0.560 |
Why?
|
| Creatine Kinase | 7 | 2004 | 691 | 0.550 |
Why?
|
| Ventricular Function, Left | 10 | 2024 | 3870 | 0.550 |
Why?
|
| Platelet Aggregation | 2 | 2010 | 805 | 0.540 |
Why?
|
| Thromboembolism | 2 | 2021 | 1016 | 0.530 |
Why?
|
| Drug Therapy, Combination | 20 | 2019 | 6499 | 0.520 |
Why?
|
| Prospective Studies | 38 | 2023 | 54263 | 0.520 |
Why?
|
| Critical Pathways | 2 | 2024 | 475 | 0.520 |
Why?
|
| Heart Arrest | 2 | 2023 | 1506 | 0.520 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2017 | 96 | 0.510 |
Why?
|
| Follow-Up Studies | 39 | 2020 | 39254 | 0.510 |
Why?
|
| Algorithms | 12 | 2023 | 13967 | 0.490 |
Why?
|
| Cholesterol | 5 | 2022 | 2925 | 0.480 |
Why?
|
| Pulsatile Flow | 4 | 2013 | 320 | 0.480 |
Why?
|
| Standard of Care | 3 | 2017 | 552 | 0.470 |
Why?
|
| Disease Management | 10 | 2024 | 2508 | 0.470 |
Why?
|
| Societies, Medical | 9 | 2024 | 3903 | 0.460 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 3 | 2017 | 334 | 0.460 |
Why?
|
| Oxygen | 2 | 2022 | 4189 | 0.460 |
Why?
|
| Fatty Acid-Binding Proteins | 3 | 2013 | 296 | 0.460 |
Why?
|
| Quality Indicators, Health Care | 1 | 2024 | 1822 | 0.460 |
Why?
|
| Biological Assay | 2 | 2015 | 630 | 0.460 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2020 | 693 | 0.450 |
Why?
|
| Exercise Test | 7 | 2017 | 2125 | 0.450 |
Why?
|
| Emergency Service, Hospital | 14 | 2023 | 7809 | 0.450 |
Why?
|
| Antirheumatic Agents | 1 | 2023 | 1374 | 0.450 |
Why?
|
| Guideline Adherence | 3 | 2020 | 2283 | 0.450 |
Why?
|
| Signal Transduction | 12 | 2017 | 23363 | 0.440 |
Why?
|
| Quality Improvement | 4 | 2024 | 3840 | 0.440 |
Why?
|
| Intracranial Hemorrhages | 9 | 2016 | 844 | 0.440 |
Why?
|
| Neointima | 2 | 2013 | 134 | 0.440 |
Why?
|
| United States | 56 | 2024 | 72363 | 0.440 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 2 | 2016 | 60 | 0.430 |
Why?
|
| Adiponectin | 2 | 2017 | 1115 | 0.430 |
Why?
|
| Respiratory Insufficiency | 4 | 2021 | 1228 | 0.430 |
Why?
|
| Risk | 19 | 2021 | 9629 | 0.430 |
Why?
|
| Ischemic Attack, Transient | 2 | 2015 | 899 | 0.420 |
Why?
|
| Antithrombins | 4 | 2008 | 313 | 0.420 |
Why?
|
| Emergency Medical Services | 9 | 2023 | 1927 | 0.420 |
Why?
|
| Coronary Angiography | 27 | 2020 | 4560 | 0.410 |
Why?
|
| Medical Staff | 1 | 2012 | 40 | 0.410 |
Why?
|
| Sensitivity and Specificity | 21 | 2021 | 14656 | 0.410 |
Why?
|
| Myocardial Revascularization | 10 | 2021 | 841 | 0.410 |
Why?
|
| Potassium | 2 | 2016 | 1318 | 0.390 |
Why?
|
| Carotid Arteries | 3 | 2014 | 951 | 0.390 |
Why?
|
| Arrhythmias, Cardiac | 8 | 2018 | 2255 | 0.380 |
Why?
|
| Pulmonary Embolism | 3 | 2023 | 2544 | 0.380 |
Why?
|
| Survival Analysis | 22 | 2019 | 10185 | 0.380 |
Why?
|
| Osteoprotegerin | 1 | 2012 | 177 | 0.380 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 222 | 0.380 |
Why?
|
| Aortic Valve Stenosis | 1 | 2024 | 2064 | 0.380 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2015 | 347 | 0.370 |
Why?
|
| Severity of Illness Index | 24 | 2021 | 15827 | 0.370 |
Why?
|
| Diagnostic Imaging | 4 | 2020 | 3526 | 0.370 |
Why?
|
| Death | 7 | 2020 | 678 | 0.360 |
Why?
|
| Respiration, Artificial | 3 | 2020 | 2623 | 0.360 |
Why?
|
| Multimedia | 1 | 2010 | 74 | 0.360 |
Why?
|
| Peptides | 5 | 2019 | 4358 | 0.350 |
Why?
|
| Decision Support Techniques | 6 | 2019 | 2002 | 0.350 |
Why?
|
| Survival Rate | 21 | 2020 | 12806 | 0.350 |
Why?
|
| Immunoassay | 8 | 2010 | 748 | 0.350 |
Why?
|
| Angioplasty, Balloon | 2 | 2012 | 597 | 0.350 |
Why?
|
| Glomerular Filtration Rate | 9 | 2023 | 2178 | 0.340 |
Why?
|
| Research Report | 3 | 2021 | 370 | 0.340 |
Why?
|
| Renin-Angiotensin System | 4 | 2020 | 739 | 0.340 |
Why?
|
| Angiopoietin-1 | 2 | 2007 | 123 | 0.340 |
Why?
|
| Isoenzymes | 7 | 2004 | 1690 | 0.340 |
Why?
|
| Models, Educational | 1 | 2012 | 372 | 0.340 |
Why?
|
| Sodium Channel Blockers | 3 | 2015 | 172 | 0.330 |
Why?
|
| Thrombin | 3 | 2021 | 593 | 0.330 |
Why?
|
| Endpoint Determination | 5 | 2018 | 597 | 0.330 |
Why?
|
| Benchmarking | 2 | 2024 | 1043 | 0.330 |
Why?
|
| Hypotension | 3 | 2024 | 883 | 0.320 |
Why?
|
| Conscious Sedation | 1 | 2013 | 529 | 0.320 |
Why?
|
| Incidence | 25 | 2023 | 21378 | 0.320 |
Why?
|
| Analgesia | 1 | 2013 | 459 | 0.320 |
Why?
|
| Healthcare Disparities | 3 | 2024 | 3381 | 0.320 |
Why?
|
| Stents | 7 | 2013 | 3303 | 0.310 |
Why?
|
| Cystatin C | 3 | 2018 | 270 | 0.310 |
Why?
|
| Retrospective Studies | 40 | 2024 | 80301 | 0.310 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2024 | 3618 | 0.310 |
Why?
|
| Clinical Trials as Topic | 15 | 2024 | 8058 | 0.310 |
Why?
|
| Pericytes | 2 | 2011 | 292 | 0.310 |
Why?
|
| Coronary Vessels | 7 | 2013 | 3112 | 0.310 |
Why?
|
| Obesity, Abdominal | 1 | 2011 | 375 | 0.300 |
Why?
|
| Tachycardia, Ventricular | 3 | 2014 | 1302 | 0.300 |
Why?
|
| Drug-Eluting Stents | 1 | 2014 | 758 | 0.300 |
Why?
|
| Renal Replacement Therapy | 2 | 2020 | 281 | 0.300 |
Why?
|
| Ethanol | 3 | 2011 | 1323 | 0.300 |
Why?
|
| Diabetes Mellitus | 7 | 2017 | 5884 | 0.300 |
Why?
|
| Heart Conduction System | 4 | 2014 | 1016 | 0.300 |
Why?
|
| Science | 1 | 2010 | 240 | 0.300 |
Why?
|
| Drug Approval | 1 | 2015 | 816 | 0.300 |
Why?
|
| Indoles | 6 | 2019 | 1830 | 0.300 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 5 | 2010 | 121 | 0.290 |
Why?
|
| Ventricular Function | 3 | 2018 | 408 | 0.290 |
Why?
|
| Cause of Death | 9 | 2024 | 3723 | 0.290 |
Why?
|
| Recombinant Proteins | 11 | 2017 | 6543 | 0.290 |
Why?
|
| Fibroblast Growth Factors | 3 | 2019 | 867 | 0.280 |
Why?
|
| Heart Transplantation | 4 | 2023 | 3217 | 0.280 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2009 | 3483 | 0.280 |
Why?
|
| Cardiology Service, Hospital | 2 | 2020 | 242 | 0.280 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2024 | 273 | 0.280 |
Why?
|
| Internationality | 3 | 2020 | 1005 | 0.280 |
Why?
|
| Oxygen Consumption | 2 | 2019 | 1840 | 0.270 |
Why?
|
| Research Design | 13 | 2024 | 6181 | 0.270 |
Why?
|
| Diabetic Angiopathies | 4 | 2018 | 822 | 0.270 |
Why?
|
| Cohort Studies | 26 | 2021 | 41317 | 0.270 |
Why?
|
| Inflammation | 15 | 2023 | 10757 | 0.270 |
Why?
|
| Thromboplastin | 2 | 2023 | 286 | 0.260 |
Why?
|
| Iron | 2 | 2022 | 1786 | 0.260 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 2 | 2022 | 33 | 0.260 |
Why?
|
| Adamantane | 3 | 2017 | 169 | 0.260 |
Why?
|
| Sterol O-Acyltransferase | 2 | 2022 | 28 | 0.260 |
Why?
|
| Cardiotonic Agents | 3 | 2021 | 546 | 0.250 |
Why?
|
| Aspirin | 10 | 2020 | 3365 | 0.250 |
Why?
|
| Aged, 80 and over | 25 | 2024 | 58947 | 0.250 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2012 | 1490 | 0.250 |
Why?
|
| Coronary Stenosis | 2 | 2010 | 820 | 0.250 |
Why?
|
| Positive-Pressure Respiration | 2 | 2019 | 634 | 0.240 |
Why?
|
| Coronary Restenosis | 4 | 2021 | 426 | 0.240 |
Why?
|
| Pulmonary Artery | 2 | 2024 | 1919 | 0.240 |
Why?
|
| Dipeptides | 3 | 2017 | 410 | 0.240 |
Why?
|
| Tissue Plasminogen Activator | 7 | 2009 | 1190 | 0.240 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2007 | 4494 | 0.240 |
Why?
|
| Evidence-Based Medicine | 10 | 2020 | 3696 | 0.240 |
Why?
|
| Cardiac Care Facilities | 3 | 2020 | 34 | 0.240 |
Why?
|
| Necrosis | 5 | 2013 | 1612 | 0.240 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2019 | 169 | 0.230 |
Why?
|
| Pulmonary Edema | 1 | 2007 | 409 | 0.230 |
Why?
|
| Diabetes Complications | 2 | 2009 | 1342 | 0.230 |
Why?
|
| Antifibrinolytic Agents | 2 | 2023 | 292 | 0.230 |
Why?
|
| Endovascular Procedures | 2 | 2020 | 2135 | 0.230 |
Why?
|
| Natriuretic Agents | 2 | 2004 | 57 | 0.220 |
Why?
|
| Brain Ischemia | 2 | 2014 | 3127 | 0.220 |
Why?
|
| Zygote | 1 | 2024 | 115 | 0.220 |
Why?
|
| Placebos | 5 | 2019 | 1672 | 0.220 |
Why?
|
| Genomics | 2 | 2017 | 5790 | 0.220 |
Why?
|
| Civil Defense | 2 | 2022 | 115 | 0.220 |
Why?
|
| Reference Values | 8 | 2011 | 4920 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 10 | 2021 | 7468 | 0.210 |
Why?
|
| Diagnosis, Differential | 7 | 2019 | 12968 | 0.210 |
Why?
|
| Neovascularization, Physiologic | 2 | 2007 | 1335 | 0.210 |
Why?
|
| Lactates | 1 | 2023 | 404 | 0.210 |
Why?
|
| Phospholipases A2, Secretory | 2 | 2013 | 31 | 0.210 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2023 | 1387 | 0.210 |
Why?
|
| Adult | 50 | 2023 | 219847 | 0.210 |
Why?
|
| Vasodilation | 1 | 2007 | 964 | 0.210 |
Why?
|
| Vascular Patency | 6 | 2016 | 901 | 0.210 |
Why?
|
| Pneumonia, Viral | 4 | 2021 | 3206 | 0.210 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 3 | 2016 | 379 | 0.200 |
Why?
|
| Comorbidity | 11 | 2020 | 10552 | 0.200 |
Why?
|
| Heart Valves | 1 | 2024 | 285 | 0.200 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2022 | 43 | 0.200 |
Why?
|
| Venous Thrombosis | 2 | 2022 | 1293 | 0.200 |
Why?
|
| ROC Curve | 5 | 2014 | 3568 | 0.200 |
Why?
|
| Phenotype | 7 | 2024 | 16543 | 0.200 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 298 | 0.200 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2023 | 2296 | 0.200 |
Why?
|
| Cytokines | 3 | 2023 | 7345 | 0.200 |
Why?
|
| Creatinine | 6 | 2018 | 1906 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2021 | 10829 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2016 | 5640 | 0.200 |
Why?
|
| Warfarin | 4 | 2024 | 1516 | 0.190 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2007 | 749 | 0.190 |
Why?
|
| Cardiac Output, Low | 4 | 2018 | 192 | 0.190 |
Why?
|
| Length of Stay | 4 | 2024 | 6472 | 0.190 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2023 | 418 | 0.190 |
Why?
|
| Endothelium, Vascular | 3 | 2011 | 4437 | 0.190 |
Why?
|
| Transcription Factors | 4 | 2024 | 12100 | 0.190 |
Why?
|
| Hospital Rapid Response Team | 1 | 2021 | 54 | 0.180 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2021 | 71 | 0.180 |
Why?
|
| Blood Platelets | 1 | 2011 | 2522 | 0.180 |
Why?
|
| Health Status Disparities | 2 | 2024 | 1819 | 0.180 |
Why?
|
| Career Choice | 2 | 2019 | 755 | 0.180 |
Why?
|
| Decision Making | 3 | 2012 | 3924 | 0.180 |
Why?
|
| Multivariate Analysis | 16 | 2014 | 12156 | 0.180 |
Why?
|
| Blood Glucose | 4 | 2010 | 6375 | 0.180 |
Why?
|
| Vascular Resistance | 1 | 2023 | 932 | 0.180 |
Why?
|
| Cell Proliferation | 4 | 2011 | 10434 | 0.180 |
Why?
|
| Cholesterol, LDL | 7 | 2017 | 2422 | 0.180 |
Why?
|
| Confidence Intervals | 6 | 2010 | 2932 | 0.180 |
Why?
|
| Renal Insufficiency | 4 | 2021 | 820 | 0.170 |
Why?
|
| Myoglobin | 5 | 2003 | 159 | 0.170 |
Why?
|
| Thrombectomy | 2 | 2023 | 707 | 0.170 |
Why?
|
| Blood Coagulation Disorders | 1 | 2023 | 349 | 0.170 |
Why?
|
| International Cooperation | 4 | 2022 | 1436 | 0.170 |
Why?
|
| Patient Advocacy | 1 | 2022 | 358 | 0.170 |
Why?
|
| Serum Amyloid A Protein | 1 | 2000 | 127 | 0.170 |
Why?
|
| Chemokine CCL2 | 4 | 2007 | 607 | 0.170 |
Why?
|
| RNA, Messenger | 7 | 2013 | 12762 | 0.170 |
Why?
|
| Assisted Circulation | 1 | 2019 | 102 | 0.170 |
Why?
|
| Kidney Diseases | 6 | 2019 | 2093 | 0.170 |
Why?
|
| Neopterin | 2 | 2011 | 56 | 0.170 |
Why?
|
| Receptors, CCR5 | 1 | 2021 | 487 | 0.170 |
Why?
|
| Carbon Dioxide | 1 | 2024 | 1145 | 0.170 |
Why?
|
| Infarction | 1 | 2021 | 248 | 0.170 |
Why?
|
| Optics and Photonics | 1 | 2021 | 305 | 0.160 |
Why?
|
| Half-Life | 3 | 2018 | 652 | 0.160 |
Why?
|
| Methylamines | 1 | 2020 | 138 | 0.160 |
Why?
|
| Extremities | 2 | 2016 | 867 | 0.160 |
Why?
|
| Tachycardia | 2 | 2007 | 603 | 0.160 |
Why?
|
| Patient Discharge | 6 | 2020 | 3475 | 0.160 |
Why?
|
| Coma | 1 | 2022 | 487 | 0.160 |
Why?
|
| Clinical Competence | 4 | 2020 | 4786 | 0.160 |
Why?
|
| Stress, Mechanical | 5 | 2008 | 1666 | 0.160 |
Why?
|
| Advisory Committees | 2 | 2020 | 789 | 0.160 |
Why?
|
| P-Selectin | 1 | 2021 | 600 | 0.160 |
Why?
|
| Disease Progression | 6 | 2023 | 13505 | 0.150 |
Why?
|
| Cyclic GMP | 1 | 2019 | 395 | 0.150 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3086 | 0.150 |
Why?
|
| Endothelial Cells | 3 | 2011 | 3537 | 0.150 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2019 | 162 | 0.150 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 1 | 2017 | 22 | 0.150 |
Why?
|
| Personnel Administration, Hospital | 1 | 2017 | 9 | 0.150 |
Why?
|
| Symporters | 1 | 2020 | 361 | 0.150 |
Why?
|
| Program Development | 1 | 2024 | 1297 | 0.150 |
Why?
|
| Odds Ratio | 15 | 2016 | 9712 | 0.150 |
Why?
|
| Hypoglycemic Agents | 5 | 2017 | 3149 | 0.150 |
Why?
|
| Diabetic Foot | 2 | 2013 | 381 | 0.150 |
Why?
|
| Drug Therapy | 1 | 2021 | 504 | 0.150 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 1935 | 0.150 |
Why?
|
| Apolipoproteins | 1 | 2000 | 320 | 0.150 |
Why?
|
| Factor Xa | 1 | 2018 | 168 | 0.150 |
Why?
|
| Venous Thromboembolism | 2 | 2023 | 1866 | 0.150 |
Why?
|
| Limit of Detection | 2 | 2020 | 280 | 0.150 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2021 | 538 | 0.140 |
Why?
|
| Glucuronidase | 1 | 2019 | 203 | 0.140 |
Why?
|
| Drug Administration Schedule | 6 | 2018 | 4900 | 0.140 |
Why?
|
| Sex Factors | 8 | 2024 | 10530 | 0.140 |
Why?
|
| Surgical Mesh | 1 | 2020 | 315 | 0.140 |
Why?
|
| Chemistry, Clinical | 2 | 2015 | 64 | 0.140 |
Why?
|
| Organizational Innovation | 1 | 2020 | 536 | 0.140 |
Why?
|
| Case-Control Studies | 12 | 2024 | 22041 | 0.140 |
Why?
|
| Biomedical Research | 4 | 2023 | 3421 | 0.140 |
Why?
|
| Plasminogen Activators | 4 | 2009 | 199 | 0.140 |
Why?
|
| Electric Countershock | 1 | 2000 | 537 | 0.140 |
Why?
|
| Germany | 1 | 2019 | 875 | 0.140 |
Why?
|
| Alanine | 6 | 2020 | 607 | 0.140 |
Why?
|
| Point-of-Care Systems | 3 | 2001 | 1208 | 0.130 |
Why?
|
| Hernia, Ventral | 1 | 2020 | 214 | 0.130 |
Why?
|
| Apolipoproteins E | 4 | 2012 | 1437 | 0.130 |
Why?
|
| Sex Characteristics | 3 | 2019 | 2627 | 0.130 |
Why?
|
| Fibrin | 2 | 2009 | 505 | 0.130 |
Why?
|
| Nuclear Proteins | 3 | 2005 | 5793 | 0.130 |
Why?
|
| Pilot Projects | 5 | 2011 | 8553 | 0.130 |
Why?
|
| Ventricular Function, Right | 2 | 2012 | 610 | 0.130 |
Why?
|
| Terminal Care | 2 | 2022 | 1759 | 0.130 |
Why?
|
| Hyperglycemia | 3 | 2010 | 1380 | 0.130 |
Why?
|
| Education, Medical, Graduate | 2 | 2019 | 2359 | 0.130 |
Why?
|
| Nitrates | 1 | 2017 | 264 | 0.130 |
Why?
|
| Internship, Nonmedical | 1 | 1995 | 7 | 0.130 |
Why?
|
| Platelet Activation | 3 | 2009 | 661 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 7 | 2024 | 1723 | 0.130 |
Why?
|
| Transfection | 3 | 2010 | 5782 | 0.130 |
Why?
|
| Antigens, Bacterial | 1 | 2021 | 1155 | 0.130 |
Why?
|
| Natriuretic Peptides | 2 | 2008 | 156 | 0.130 |
Why?
|
| Cells, Cultured | 6 | 2013 | 18968 | 0.130 |
Why?
|
| RNA, Small Interfering | 3 | 2013 | 3443 | 0.130 |
Why?
|
| Certification | 1 | 2019 | 423 | 0.130 |
Why?
|
| Mortality | 5 | 2020 | 2916 | 0.130 |
Why?
|
| Communicable Disease Control | 1 | 2022 | 844 | 0.120 |
Why?
|
| Reproducibility of Results | 12 | 2021 | 20048 | 0.120 |
Why?
|
| Administration, Oral | 6 | 2024 | 4044 | 0.120 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2023 | 1583 | 0.120 |
Why?
|
| Psychology, Clinical | 1 | 1995 | 42 | 0.120 |
Why?
|
| Apoptosis | 5 | 2011 | 9497 | 0.120 |
Why?
|
| Prevalence | 6 | 2019 | 15687 | 0.120 |
Why?
|
| Inservice Training | 1 | 2017 | 376 | 0.120 |
Why?
|
| HIV Antibodies | 1 | 2021 | 1300 | 0.120 |
Why?
|
| Renal Dialysis | 2 | 2021 | 1802 | 0.120 |
Why?
|
| Education, Graduate | 1 | 1995 | 75 | 0.120 |
Why?
|
| Carotid Artery Diseases | 2 | 2011 | 881 | 0.120 |
Why?
|
| Primary Prevention | 2 | 2012 | 1207 | 0.120 |
Why?
|
| Electrocardiography, Ambulatory | 4 | 2011 | 578 | 0.120 |
Why?
|
| Prosthesis-Related Infections | 1 | 2020 | 486 | 0.120 |
Why?
|
| Canada | 5 | 2020 | 2128 | 0.120 |
Why?
|
| Benzaldehydes | 3 | 2018 | 59 | 0.120 |
Why?
|
| Patient Selection | 7 | 2019 | 4276 | 0.110 |
Why?
|
| Reference Standards | 4 | 2019 | 1004 | 0.110 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2014 | 71 | 0.110 |
Why?
|
| Microcirculation | 2 | 2017 | 1279 | 0.110 |
Why?
|
| Limb Salvage | 1 | 2016 | 466 | 0.110 |
Why?
|
| Adenosine | 2 | 2016 | 833 | 0.110 |
Why?
|
| Rats | 7 | 2014 | 23695 | 0.110 |
Why?
|
| Recovery of Function | 3 | 2019 | 2982 | 0.110 |
Why?
|
| Phosphorylcholine | 1 | 2014 | 153 | 0.110 |
Why?
|
| Gene Expression Regulation | 6 | 2013 | 11902 | 0.110 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2017 | 498 | 0.110 |
Why?
|
| DNA-Binding Proteins | 3 | 2005 | 9590 | 0.110 |
Why?
|
| Fumarates | 2 | 2013 | 131 | 0.110 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2017 | 1520 | 0.110 |
Why?
|
| Health Care Costs | 3 | 2019 | 3257 | 0.110 |
Why?
|
| Professional Practice | 1 | 1995 | 313 | 0.110 |
Why?
|
| Placebo Effect | 2 | 2014 | 511 | 0.110 |
Why?
|
| Pyrrolidines | 5 | 2007 | 338 | 0.110 |
Why?
|
| Multipotent Stem Cells | 1 | 2014 | 200 | 0.110 |
Why?
|
| Temporomandibular Joint Disorders | 1 | 1996 | 220 | 0.110 |
Why?
|
| Lecithins | 2 | 2022 | 17 | 0.110 |
Why?
|
| Lipoproteins, LDL | 2 | 2006 | 641 | 0.110 |
Why?
|
| Weight Loss | 1 | 2024 | 2683 | 0.110 |
Why?
|
| Career Mobility | 1 | 1995 | 258 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 3 | 2008 | 2696 | 0.100 |
Why?
|
| Carotid Artery Injuries | 1 | 2013 | 96 | 0.100 |
Why?
|
| Blood Coagulation | 3 | 2009 | 1156 | 0.100 |
Why?
|
| Oximes | 3 | 2018 | 306 | 0.100 |
Why?
|
| Outpatients | 1 | 2020 | 1606 | 0.100 |
Why?
|
| Postoperative Hemorrhage | 2 | 2006 | 422 | 0.100 |
Why?
|
| Arteries | 1 | 2017 | 1126 | 0.100 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 1882 | 0.100 |
Why?
|
| Orthodontic Appliances | 1 | 1992 | 40 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 5 | 2005 | 9196 | 0.100 |
Why?
|
| Ankle Brachial Index | 1 | 2013 | 163 | 0.100 |
Why?
|
| Valine | 2 | 2013 | 409 | 0.100 |
Why?
|
| Family | 1 | 2023 | 3189 | 0.100 |
Why?
|
| Hirudins | 3 | 2008 | 194 | 0.100 |
Why?
|
| United States Food and Drug Administration | 3 | 2018 | 1675 | 0.100 |
Why?
|
| Streptokinase | 2 | 2009 | 187 | 0.100 |
Why?
|
| Lipids | 1 | 2023 | 3336 | 0.100 |
Why?
|
| Up-Regulation | 3 | 2020 | 4127 | 0.100 |
Why?
|
| Retreatment | 2 | 2012 | 600 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 3804 | 0.100 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 944 | 0.100 |
Why?
|
| Quality of Life | 5 | 2020 | 13300 | 0.100 |
Why?
|
| Genetic Loci | 2 | 2012 | 2618 | 0.100 |
Why?
|
| Joint Diseases | 1 | 1996 | 458 | 0.100 |
Why?
|
| Medication Therapy Management | 4 | 2012 | 132 | 0.100 |
Why?
|
| Epidemiologic Studies | 1 | 2015 | 670 | 0.100 |
Why?
|
| Amides | 2 | 2013 | 448 | 0.100 |
Why?
|
| Angiotensins | 2 | 2023 | 143 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 3 | 2021 | 2469 | 0.100 |
Why?
|
| Clinical Protocols | 6 | 2013 | 1439 | 0.100 |
Why?
|
| Gingivitis | 1 | 1992 | 124 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2021 | 4938 | 0.090 |
Why?
|
| Inpatients | 2 | 2020 | 2578 | 0.090 |
Why?
|
| Probability | 3 | 2019 | 2476 | 0.090 |
Why?
|
| Catalysis | 1 | 2013 | 775 | 0.090 |
Why?
|
| Massachusetts | 2 | 2014 | 8805 | 0.090 |
Why?
|
| Cellulitis | 1 | 2013 | 208 | 0.090 |
Why?
|
| Hemoglobins | 2 | 2009 | 1521 | 0.090 |
Why?
|
| Kidney | 3 | 2023 | 7072 | 0.090 |
Why?
|
| Aortic Coarctation | 1 | 2013 | 282 | 0.090 |
Why?
|
| Intestines | 1 | 2020 | 1907 | 0.090 |
Why?
|
| Blood Pressure | 3 | 2022 | 8523 | 0.090 |
Why?
|
| Animals | 21 | 2021 | 167940 | 0.090 |
Why?
|
| Amputation Stumps | 1 | 2010 | 38 | 0.090 |
Why?
|
| Chlorhexidine | 1 | 1992 | 160 | 0.090 |
Why?
|
| Morpholines | 1 | 2014 | 583 | 0.090 |
Why?
|
| Congresses as Topic | 3 | 2024 | 804 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2020 | 1940 | 0.090 |
Why?
|
| Survivors | 1 | 2021 | 2367 | 0.090 |
Why?
|
| Norway | 1 | 2012 | 497 | 0.090 |
Why?
|
| Pandemics | 5 | 2023 | 8621 | 0.090 |
Why?
|
| Tissue Donors | 1 | 2020 | 2314 | 0.090 |
Why?
|
| Databases, Factual | 3 | 2020 | 8018 | 0.090 |
Why?
|
| Device Removal | 3 | 2024 | 634 | 0.090 |
Why?
|
| Validation Studies as Topic | 1 | 2010 | 163 | 0.090 |
Why?
|
| Self Administration | 1 | 1991 | 390 | 0.090 |
Why?
|
| Body Mass Index | 5 | 2024 | 12901 | 0.090 |
Why?
|
| Age Factors | 9 | 2022 | 18415 | 0.090 |
Why?
|
| RNA Interference | 2 | 2010 | 2846 | 0.090 |
Why?
|
| Patient Education as Topic | 2 | 2009 | 2311 | 0.090 |
Why?
|
| Hospitals | 2 | 2022 | 3929 | 0.090 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2007 | 129 | 0.090 |
Why?
|
| Heart | 2 | 2023 | 4392 | 0.090 |
Why?
|
| Task Performance and Analysis | 2 | 1994 | 759 | 0.090 |
Why?
|
| Hyperplasia | 1 | 2013 | 1158 | 0.090 |
Why?
|
| Health Status | 3 | 2019 | 4081 | 0.090 |
Why?
|
| Ferritins | 2 | 2023 | 598 | 0.080 |
Why?
|
| Specialization | 3 | 2020 | 779 | 0.080 |
Why?
|
| Glucose | 2 | 2020 | 4361 | 0.080 |
Why?
|
| Texas | 5 | 2010 | 401 | 0.080 |
Why?
|
| Education | 1 | 2012 | 535 | 0.080 |
Why?
|
| Europe | 4 | 2024 | 3433 | 0.080 |
Why?
|
| Ventricular Premature Complexes | 1 | 2010 | 113 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2011 | 409 | 0.080 |
Why?
|
| Bacteria | 1 | 2020 | 2196 | 0.080 |
Why?
|
| Exercise Tolerance | 2 | 2017 | 826 | 0.080 |
Why?
|
| Interleukin-6 | 2 | 2017 | 3207 | 0.080 |
Why?
|
| Immunoglobulin M | 1 | 2014 | 1529 | 0.080 |
Why?
|
| Combined Modality Therapy | 4 | 2009 | 8551 | 0.080 |
Why?
|
| Aircraft | 1 | 1990 | 126 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 4355 | 0.080 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2011 | 238 | 0.080 |
Why?
|
| Lipoprotein(a) | 1 | 2013 | 499 | 0.080 |
Why?
|
| Immunoglobulin Fab Fragments | 4 | 2004 | 465 | 0.080 |
Why?
|
| Data Collection | 1 | 2018 | 3317 | 0.080 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2010 | 155 | 0.080 |
Why?
|
| Age Distribution | 1 | 2014 | 2893 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 3 | 2010 | 5784 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 1 | 2013 | 1066 | 0.080 |
Why?
|
| DNA | 2 | 2013 | 7236 | 0.080 |
Why?
|
| Diastole | 2 | 2024 | 788 | 0.080 |
Why?
|
| Women's Health | 1 | 2018 | 2057 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 3159 | 0.080 |
Why?
|
| Hypertension | 2 | 2022 | 8595 | 0.080 |
Why?
|
| Aldosterone | 1 | 2013 | 868 | 0.080 |
Why?
|
| Opportunistic Infections | 1 | 2011 | 377 | 0.080 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 1134 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2005 | 11480 | 0.070 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2013 | 989 | 0.070 |
Why?
|
| Lipoproteins, HDL | 2 | 2022 | 667 | 0.070 |
Why?
|
| Alcohol Drinking | 2 | 2011 | 4012 | 0.070 |
Why?
|
| Receptor, TIE-1 | 1 | 2007 | 13 | 0.070 |
Why?
|
| Waist Circumference | 1 | 2011 | 922 | 0.070 |
Why?
|
| Takotsubo Cardiomyopathy | 2 | 2020 | 124 | 0.070 |
Why?
|
| Apolipoprotein A-I | 1 | 2009 | 297 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 435 | 0.070 |
Why?
|
| Genetic Heterogeneity | 1 | 2010 | 724 | 0.070 |
Why?
|
| Government Regulation | 1 | 2011 | 526 | 0.070 |
Why?
|
| Apolipoproteins B | 1 | 2009 | 388 | 0.070 |
Why?
|
| Counseling | 1 | 1995 | 1550 | 0.070 |
Why?
|
| Endothelin-1 | 2 | 2023 | 302 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2024 | 4763 | 0.070 |
Why?
|
| Cell Division | 2 | 2024 | 4462 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 1399 | 0.070 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2005 | 346 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 926 | 0.070 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 2222 | 0.070 |
Why?
|
| Myocytes, Cardiac | 2 | 2013 | 1656 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2014 | 2424 | 0.070 |
Why?
|
| Anthropometry | 1 | 2011 | 1348 | 0.070 |
Why?
|
| Receptor, TIE-2 | 1 | 2007 | 177 | 0.070 |
Why?
|
| Sentinel Surveillance | 1 | 2008 | 293 | 0.070 |
Why?
|
| Injections, Intramuscular | 2 | 2021 | 553 | 0.070 |
Why?
|
| Ventricular Pressure | 1 | 2007 | 204 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2008 | 428 | 0.070 |
Why?
|
| Cell Line | 3 | 2014 | 15626 | 0.070 |
Why?
|
| Health Resources | 2 | 2024 | 936 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2012 | 1576 | 0.070 |
Why?
|
| India | 1 | 2013 | 2346 | 0.070 |
Why?
|
| Glucose Tolerance Test | 1 | 2009 | 1174 | 0.070 |
Why?
|
| Phospholipases A | 1 | 2006 | 204 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2013 | 1956 | 0.060 |
Why?
|
| Drug Industry | 1 | 2011 | 789 | 0.060 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 2138 | 0.060 |
Why?
|
| Acute-Phase Proteins | 1 | 2006 | 250 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2010 | 2295 | 0.060 |
Why?
|
| Photons | 1 | 2008 | 581 | 0.060 |
Why?
|
| von Willebrand Factor | 2 | 2007 | 673 | 0.060 |
Why?
|
| Metabolism | 1 | 2005 | 193 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 1137 | 0.060 |
Why?
|
| Body Height | 1 | 2010 | 1570 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2012 | 2777 | 0.060 |
Why?
|
| Young Adult | 7 | 2021 | 58673 | 0.060 |
Why?
|
| Adrenomedullin | 2 | 2016 | 85 | 0.060 |
Why?
|
| Emergencies | 2 | 2019 | 1217 | 0.060 |
Why?
|
| Models, Animal | 2 | 2011 | 2117 | 0.060 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2007 | 488 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2009 | 709 | 0.060 |
Why?
|
| Fluoroquinolones | 4 | 2007 | 309 | 0.060 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2005 | 282 | 0.060 |
Why?
|
| Aromatase | 1 | 2004 | 147 | 0.060 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2006 | 503 | 0.060 |
Why?
|
| Longitudinal Studies | 3 | 2014 | 14482 | 0.050 |
Why?
|
| Matrix Metalloproteinases | 1 | 2006 | 392 | 0.050 |
Why?
|
| Iceland | 1 | 2023 | 184 | 0.050 |
Why?
|
| Anti-Infective Agents | 2 | 2007 | 982 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2005 | 413 | 0.050 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2023 | 98 | 0.050 |
Why?
|
| Osteoarthritis | 1 | 2011 | 1055 | 0.050 |
Why?
|
| RNA | 1 | 2013 | 2721 | 0.050 |
Why?
|
| Leukocyte Count | 2 | 2008 | 1600 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2013 | 2918 | 0.050 |
Why?
|
| Neutrophils | 2 | 2023 | 3770 | 0.050 |
Why?
|
| Safety Management | 1 | 2008 | 760 | 0.050 |
Why?
|
| Cobalt | 1 | 2003 | 155 | 0.050 |
Why?
|
| Gene Duplication | 1 | 2004 | 314 | 0.050 |
Why?
|
| Linear Models | 1 | 2013 | 5876 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2009 | 1434 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2006 | 1128 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 1388 | 0.050 |
Why?
|
| Adenosine Monophosphate | 2 | 2020 | 283 | 0.050 |
Why?
|
| Receptors, Erythropoietin | 1 | 2022 | 144 | 0.050 |
Why?
|
| Chronic Disease | 3 | 2021 | 9283 | 0.050 |
Why?
|
| Monocytes | 2 | 2012 | 2574 | 0.050 |
Why?
|
| Natriuresis | 1 | 2002 | 105 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5324 | 0.050 |
Why?
|
| Analysis of Variance | 4 | 2018 | 6242 | 0.050 |
Why?
|
| Ventral Thalamic Nuclei | 1 | 2001 | 43 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 3 | 2004 | 4409 | 0.050 |
Why?
|
| Mice | 8 | 2017 | 81216 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2022 | 206 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2011 | 1529 | 0.050 |
Why?
|
| Reperfusion Injury | 1 | 2008 | 1023 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 2651 | 0.050 |
Why?
|
| Research | 2 | 2023 | 1973 | 0.050 |
Why?
|
| Patient Compliance | 1 | 1991 | 2689 | 0.050 |
Why?
|
| Drug Delivery Systems | 2 | 2018 | 2218 | 0.050 |
Why?
|
| Statistics as Topic | 5 | 2005 | 2363 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2282 | 0.050 |
Why?
|
| Therapeutic Equipoise | 1 | 2020 | 28 | 0.050 |
Why?
|
| Myelin P2 Protein | 1 | 2000 | 20 | 0.050 |
Why?
|
| Infant | 2 | 2021 | 36030 | 0.050 |
Why?
|
| Anti-Obesity Agents | 1 | 2024 | 229 | 0.050 |
Why?
|
| Receptors, Transferrin | 1 | 2022 | 291 | 0.050 |
Why?
|
| Ceramides | 1 | 2022 | 200 | 0.050 |
Why?
|
| Calibration | 2 | 2017 | 816 | 0.050 |
Why?
|
| Tremor | 1 | 2001 | 187 | 0.050 |
Why?
|
| Sodium | 2 | 2020 | 1601 | 0.050 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2020 | 60 | 0.040 |
Why?
|
| Receptors, Angiotensin | 1 | 2020 | 141 | 0.040 |
Why?
|
| Retina | 1 | 2011 | 2635 | 0.040 |
Why?
|
| Hemofiltration | 1 | 2020 | 59 | 0.040 |
Why?
|
| Adolescent | 9 | 2023 | 87747 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2021 | 225 | 0.040 |
Why?
|
| England | 1 | 2021 | 526 | 0.040 |
Why?
|
| Catheters | 1 | 2023 | 425 | 0.040 |
Why?
|
| Protein Binding | 2 | 2021 | 9336 | 0.040 |
Why?
|
| Polypropylenes | 1 | 2020 | 63 | 0.040 |
Why?
|
| Vital Signs | 1 | 2021 | 142 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2003 | 674 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 22025 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 1174 | 0.040 |
Why?
|
| Takayasu Arteritis | 1 | 2000 | 95 | 0.040 |
Why?
|
| Wound Healing | 1 | 2010 | 2786 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2020 | 334 | 0.040 |
Why?
|
| Actins | 2 | 2005 | 2049 | 0.040 |
Why?
|
| Platelet Function Tests | 1 | 2021 | 303 | 0.040 |
Why?
|
| Primates | 1 | 2021 | 523 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 3448 | 0.040 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2023 | 613 | 0.040 |
Why?
|
| Physical Chromosome Mapping | 1 | 1999 | 182 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 4286 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 3 | 2020 | 5507 | 0.040 |
Why?
|
| Treatment Failure | 3 | 2016 | 2646 | 0.040 |
Why?
|
| Chloroquine | 1 | 2020 | 277 | 0.040 |
Why?
|
| Epidemiologic Methods | 3 | 2008 | 1344 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1999 | 228 | 0.040 |
Why?
|
| Hyperkalemia | 1 | 2021 | 231 | 0.040 |
Why?
|
| Computer Security | 1 | 2020 | 260 | 0.040 |
Why?
|
| Communication Barriers | 1 | 2022 | 415 | 0.040 |
Why?
|
| Sports | 1 | 2024 | 700 | 0.040 |
Why?
|
| Phospholipids | 1 | 2022 | 789 | 0.040 |
Why?
|
| Cattle | 3 | 2011 | 3847 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 1408 | 0.040 |
Why?
|
| Aneurysm, False | 1 | 2000 | 257 | 0.040 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 6830 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 2020 | 429 | 0.040 |
Why?
|
| Hypercholesterolemia | 1 | 2005 | 1155 | 0.040 |
Why?
|
| Polyesters | 1 | 2020 | 372 | 0.040 |
Why?
|
| Device Approval | 1 | 2019 | 165 | 0.040 |
Why?
|
| Public Health | 2 | 2022 | 2655 | 0.040 |
Why?
|
| Cholesterol, HDL | 3 | 2011 | 1817 | 0.040 |
Why?
|
| Logistic Models | 5 | 2020 | 13311 | 0.040 |
Why?
|
| Echocardiography | 3 | 2017 | 4980 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2009 | 1938 | 0.040 |
Why?
|
| Ventilator Weaning | 1 | 2018 | 161 | 0.040 |
Why?
|
| Angiography | 1 | 2022 | 1605 | 0.040 |
Why?
|
| Heart Rate | 3 | 2017 | 4169 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2004 | 7854 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2009 | 2163 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2012 | 4361 | 0.040 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 25928 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2023 | 934 | 0.040 |
Why?
|
| Plasma | 1 | 2020 | 584 | 0.030 |
Why?
|
| Phospholipases A2 | 2 | 2007 | 197 | 0.030 |
Why?
|
| Regression Analysis | 3 | 2001 | 6361 | 0.030 |
Why?
|
| Docosahexaenoic Acids | 1 | 2023 | 912 | 0.030 |
Why?
|
| Carbohydrate Metabolism | 1 | 2017 | 262 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2001 | 5073 | 0.030 |
Why?
|
| Virus Internalization | 1 | 2020 | 494 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2005 | 3735 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2011 | 3451 | 0.030 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 428 | 0.030 |
Why?
|
| Cardiac Output | 1 | 2018 | 837 | 0.030 |
Why?
|
| Public Policy | 2 | 2012 | 560 | 0.030 |
Why?
|
| Aortic Aneurysm | 1 | 2000 | 646 | 0.030 |
Why?
|
| Genome | 1 | 2024 | 1739 | 0.030 |
Why?
|
| Uric Acid | 1 | 2022 | 807 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 859 | 0.030 |
Why?
|
| Communication | 1 | 1990 | 3846 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 3763 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2021 | 2569 | 0.030 |
Why?
|
| Hospital Units | 1 | 2016 | 142 | 0.030 |
Why?
|
| Ontario | 1 | 2016 | 405 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2023 | 2612 | 0.030 |
Why?
|
| Respiratory Rate | 1 | 2016 | 175 | 0.030 |
Why?
|
| False Positive Reactions | 2 | 2007 | 956 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2021 | 966 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2006 | 3107 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2012 | 15766 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2011 | 18134 | 0.030 |
Why?
|
| Body Weight | 2 | 2024 | 4613 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2020 | 1137 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2023 | 2837 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 7400 | 0.030 |
Why?
|
| Stem Cells | 2 | 2021 | 3525 | 0.030 |
Why?
|
| Carbon Monoxide | 1 | 2017 | 541 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2023 | 2204 | 0.030 |
Why?
|
| Vasoconstrictor Agents | 1 | 2017 | 651 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 1724 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2017 | 1133 | 0.030 |
Why?
|
| Morbidity | 1 | 2019 | 1765 | 0.030 |
Why?
|
| Aerospace Medicine | 1 | 1994 | 95 | 0.030 |
Why?
|
| Galectins | 1 | 2016 | 282 | 0.030 |
Why?
|
| Obesity | 3 | 2024 | 12915 | 0.030 |
Why?
|
| Alcoholic Intoxication | 1 | 1994 | 174 | 0.030 |
Why?
|
| Antimalarials | 1 | 2020 | 907 | 0.030 |
Why?
|
| Intraoperative Complications | 2 | 2012 | 1186 | 0.030 |
Why?
|
| Oximetry | 1 | 2016 | 461 | 0.030 |
Why?
|
| Informed Consent | 1 | 2019 | 1007 | 0.030 |
Why?
|
| Brugada Syndrome | 1 | 2014 | 95 | 0.030 |
Why?
|
| Pregnancy | 3 | 2012 | 29725 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2020 | 2127 | 0.030 |
Why?
|
| Forecasting | 1 | 2022 | 2931 | 0.030 |
Why?
|
| Gingival Pocket | 1 | 1992 | 7 | 0.030 |
Why?
|
| Gingival Hemorrhage | 1 | 1992 | 49 | 0.030 |
Why?
|
| Dental Plaque Index | 1 | 1992 | 95 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2020 | 1132 | 0.030 |
Why?
|
| Cell Movement | 1 | 2004 | 5206 | 0.030 |
Why?
|
| Periodontal Index | 1 | 1992 | 151 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 3466 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 2 | 2012 | 2178 | 0.020 |
Why?
|
| Respiration | 1 | 2018 | 1648 | 0.020 |
Why?
|
| Anterior Cruciate Ligament | 1 | 1995 | 423 | 0.020 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2017 | 572 | 0.020 |
Why?
|
| Clinical Enzyme Tests | 1 | 2011 | 114 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2002 | 5201 | 0.020 |
Why?
|
| Toe Phalanges | 1 | 2011 | 9 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2014 | 912 | 0.020 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2012 | 192 | 0.020 |
Why?
|
| Factitious Disorders | 1 | 2011 | 39 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2021 | 5873 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 2061 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 2022 | 1470 | 0.020 |
Why?
|
| Interleukin-11 | 1 | 2010 | 59 | 0.020 |
Why?
|
| Therapeutic Irrigation | 1 | 1992 | 292 | 0.020 |
Why?
|
| Growth Hormone | 1 | 1993 | 568 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2016 | 1172 | 0.020 |
Why?
|
| Diclofenac | 1 | 2011 | 67 | 0.020 |
Why?
|
| Family Health | 1 | 1996 | 1258 | 0.020 |
Why?
|
| Aging | 1 | 1990 | 8641 | 0.020 |
Why?
|
| Skin Care | 1 | 2010 | 57 | 0.020 |
Why?
|
| Smad3 Protein | 1 | 2010 | 168 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2023 | 3811 | 0.020 |
Why?
|
| Radio | 1 | 1990 | 9 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2011 | 238 | 0.020 |
Why?
|
| Exudates and Transudates | 1 | 2010 | 175 | 0.020 |
Why?
|
| Ultrasonic Therapy | 1 | 1992 | 215 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 2753 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2000 | 2804 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2017 | 2434 | 0.020 |
Why?
|
| Bayes Theorem | 2 | 2008 | 2325 | 0.020 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2012 | 269 | 0.020 |
Why?
|
| Dyspnea | 2 | 2008 | 1352 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1992 | 596 | 0.020 |
Why?
|
| Fever | 1 | 2017 | 1618 | 0.020 |
Why?
|
| Biotransformation | 1 | 2009 | 165 | 0.020 |
Why?
|
| Self-Assessment | 1 | 1991 | 393 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2017 | 14396 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2012 | 20484 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 936 | 0.020 |
Why?
|
| Ambulatory Care | 2 | 2011 | 2783 | 0.020 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2012 | 560 | 0.020 |
Why?
|
| Propensity Score | 1 | 2016 | 1918 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 558 | 0.020 |
Why?
|
| Medical Assistance | 1 | 2009 | 107 | 0.020 |
Why?
|
| Fibrinolysis | 1 | 2010 | 332 | 0.020 |
Why?
|
| Sulfones | 1 | 2011 | 447 | 0.020 |
Why?
|
| Joint Instability | 1 | 1996 | 795 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 1992 | 1577 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2009 | 206 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2011 | 1490 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 3613 | 0.020 |
Why?
|
| Smoking | 2 | 2002 | 9070 | 0.020 |
Why?
|
| Renin | 1 | 2010 | 636 | 0.020 |
Why?
|
| Reading | 1 | 1991 | 530 | 0.020 |
Why?
|
| Pregnancy, Animal | 1 | 1988 | 124 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2024 | 9388 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2020 | 3061 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2024 | 4370 | 0.020 |
Why?
|
| Hematocrit | 1 | 2009 | 630 | 0.020 |
Why?
|
| Thyroidectomy | 1 | 1993 | 903 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2012 | 1181 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 2012 | 1206 | 0.020 |
Why?
|
| Foot | 1 | 2011 | 573 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 6067 | 0.020 |
Why?
|
| Perfusion | 1 | 2011 | 1376 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2013 | 1097 | 0.020 |
Why?
|
| Foreign Bodies | 1 | 2011 | 397 | 0.020 |
Why?
|
| Knee Joint | 1 | 1995 | 1662 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 2001 | 3202 | 0.020 |
Why?
|
| Drug Design | 1 | 2012 | 1062 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2007 | 574 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 1993 | 1169 | 0.020 |
Why?
|
| Spleen | 1 | 2012 | 2298 | 0.020 |
Why?
|
| Life Style | 1 | 2017 | 3888 | 0.020 |
Why?
|
| Antithrombin III | 1 | 2006 | 129 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4573 | 0.020 |
Why?
|
| Lactation | 1 | 1988 | 395 | 0.020 |
Why?
|
| Safety | 1 | 2010 | 1149 | 0.020 |
Why?
|
| Leg | 1 | 2011 | 1091 | 0.020 |
Why?
|
| Angiogenic Proteins | 1 | 2006 | 101 | 0.020 |
Why?
|
| Prothrombin | 1 | 2006 | 191 | 0.020 |
Why?
|
| Citric Acid | 1 | 2005 | 123 | 0.020 |
Why?
|
| Fetus | 1 | 1993 | 1859 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2022 | 42034 | 0.020 |
Why?
|
| Hemangioendothelioma | 1 | 1986 | 111 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2007 | 377 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2006 | 214 | 0.020 |
Why?
|
| Mental Recall | 1 | 1991 | 1205 | 0.020 |
Why?
|
| Selenium | 1 | 1988 | 416 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2010 | 718 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2007 | 818 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2007 | 1061 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2010 | 909 | 0.020 |
Why?
|
| Truth Disclosure | 1 | 2009 | 432 | 0.020 |
Why?
|
| Monensin | 1 | 2004 | 30 | 0.020 |
Why?
|
| Brefeldin A | 1 | 2004 | 68 | 0.010 |
Why?
|
| Homozygote | 1 | 2009 | 1786 | 0.010 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 267 | 0.010 |
Why?
|
| Hydroxytestosterones | 1 | 2004 | 3 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2007 | 1265 | 0.010 |
Why?
|
| Enzymes | 1 | 2006 | 261 | 0.010 |
Why?
|
| Insurance Claim Review | 1 | 2009 | 737 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2011 | 1395 | 0.010 |
Why?
|
| Child | 3 | 2022 | 79758 | 0.010 |
Why?
|
| Boston | 1 | 2017 | 9282 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 1395 | 0.010 |
Why?
|
| Attitude of Health Personnel | 2 | 2010 | 3870 | 0.010 |
Why?
|
| Vitamin E | 1 | 1988 | 872 | 0.010 |
Why?
|
| Calcium | 2 | 2009 | 5726 | 0.010 |
Why?
|
| Life Tables | 1 | 2004 | 365 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2010 | 3605 | 0.010 |
Why?
|
| Growth Substances | 1 | 2006 | 768 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2011 | 5039 | 0.010 |
Why?
|
| Solubility | 1 | 2005 | 1088 | 0.010 |
Why?
|
| Tritium | 1 | 2004 | 707 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2009 | 1679 | 0.010 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2004 | 352 | 0.010 |
Why?
|
| Haplotypes | 1 | 2009 | 2764 | 0.010 |
Why?
|
| Fees, Pharmaceutical | 1 | 2002 | 66 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2007 | 1426 | 0.010 |
Why?
|
| Heterozygote | 1 | 2009 | 2797 | 0.010 |
Why?
|
| Alleles | 1 | 2013 | 6900 | 0.010 |
Why?
|
| Genome-Wide Association Study | 2 | 2012 | 12602 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 1549 | 0.010 |
Why?
|
| Memory | 1 | 1991 | 2179 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2008 | 1478 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2010 | 2028 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2004 | 629 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2007 | 785 | 0.010 |
Why?
|
| Time | 1 | 2003 | 545 | 0.010 |
Why?
|
| Weight Gain | 1 | 2011 | 2347 | 0.010 |
Why?
|
| Cell Survival | 1 | 2011 | 5796 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2005 | 1375 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2009 | 1902 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 6457 | 0.010 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2006 | 853 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 1975 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2005 | 1132 | 0.010 |
Why?
|
| Testis | 1 | 2004 | 794 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2010 | 3514 | 0.010 |
Why?
|
| Health Policy | 1 | 2012 | 2678 | 0.010 |
Why?
|
| Radiography | 1 | 2011 | 6965 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2012 | 3390 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2004 | 1792 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 1602 | 0.010 |
Why?
|
| Diet | 1 | 2017 | 8008 | 0.010 |
Why?
|
| Ovary | 1 | 2004 | 959 | 0.010 |
Why?
|
| Sequence Tagged Sites | 1 | 1999 | 94 | 0.010 |
Why?
|
| Chromosomes, Artificial, Yeast | 1 | 1999 | 113 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 2011 | 2041 | 0.010 |
Why?
|
| Arm | 1 | 2001 | 583 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 3531 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 2006 | 1180 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 11064 | 0.010 |
Why?
|
| Genotype | 1 | 2012 | 12959 | 0.010 |
Why?
|
| Pericardium | 1 | 2001 | 675 | 0.010 |
Why?
|
| Lymphoma | 1 | 1986 | 1899 | 0.010 |
Why?
|
| Triglycerides | 1 | 2004 | 2476 | 0.010 |
Why?
|
| Estradiol | 1 | 2004 | 1932 | 0.010 |
Why?
|
| Macrophages | 1 | 2011 | 5745 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 6378 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2012 | 4649 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2010 | 36247 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 2007 | 1919 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 2852 | 0.010 |
Why?
|
| Calcinosis | 1 | 2004 | 1478 | 0.010 |
Why?
|
| Electric Stimulation Therapy | 1 | 2001 | 613 | 0.010 |
Why?
|
| Anemia | 1 | 2005 | 1511 | 0.010 |
Why?
|
| Pain | 1 | 2010 | 5066 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2004 | 1884 | 0.010 |
Why?
|
| HIV Infections | 1 | 2021 | 17159 | 0.010 |
Why?
|
| Placenta | 1 | 2004 | 1701 | 0.010 |
Why?
|
| DNA Primers | 1 | 1999 | 2819 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2001 | 1826 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2004 | 1915 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1999 | 1526 | 0.010 |
Why?
|
| Cognition | 1 | 1991 | 6948 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 2874 | 0.010 |
Why?
|
| Biomedical Engineering | 1 | 1995 | 289 | 0.010 |
Why?
|
| Swine | 1 | 2004 | 5902 | 0.010 |
Why?
|
| Physicians | 1 | 1991 | 4590 | 0.010 |
Why?
|
| Testosterone | 1 | 2004 | 2469 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2013 | 26168 | 0.010 |
Why?
|
| Weight-Bearing | 1 | 1995 | 518 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 866 | 0.010 |
Why?
|
| Autoradiography | 1 | 1993 | 730 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1993 | 1544 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 4923 | 0.010 |
Why?
|
| Sheep | 1 | 1993 | 1441 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 17766 | 0.010 |
Why?
|
| Thyroxine | 1 | 1993 | 667 | 0.010 |
Why?
|
| Models, Biological | 1 | 2004 | 9468 | 0.000 |
Why?
|
| Base Sequence | 1 | 1999 | 12447 | 0.000 |
Why?
|
| Frozen Sections | 1 | 1986 | 153 | 0.000 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1993 | 1920 | 0.000 |
Why?
|
| Gestational Age | 1 | 1993 | 3564 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 2006 | 15680 | 0.000 |
Why?
|
| Blood Vessels | 1 | 1986 | 1112 | 0.000 |
Why?
|
| Frontal Lobe | 1 | 1986 | 1422 | 0.000 |
Why?
|
| Antigens, Neoplasm | 1 | 1986 | 1999 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1986 | 4739 | 0.000 |
Why?
|
| Skin | 1 | 1986 | 4468 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1986 | 10183 | 0.000 |
Why?
|